Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChronicStatinMig
NCT06485336Phase 2
Key facts
- Status
- Recruiting
- Start
- May 2024
- Primary completion
- Dec 2028
- Countries
- 1
- Sponsor
- St. Olavs University Hospital
- Modality
- Small Molecules
- Drugs
- atorvastatin
- Conditions
- chronic migraine
01
Overview
Phase 2, randomised, triple-blind trial in chronic migraine comparing Atorvastatin 40mg with Placebo (2 arms). Primary endpoint: Number of migraine days at 4 weeks. Started May 2024; status: recruiting.
02
Design
2 arms- Study design
- RandomizedTriple-blind
Atorvastatin 40mg
Atorvastatin 40mg once daily for 84 days
Placebo
Placebo once daily for 84 days
03
Who it enrols
Adults aged 18-64 with chronic migraine (>=15 headache days/month, >=8 migraine days/month) starting before age 50. Excludes pregnant/lactating women, those with significant comorbidities, hypersensitivity to statins, or recent use of other migraine prophylactics.
04
Endpoints
Primary
Number of migraine days
Secondary
Number of responders
Rate of adverse events
Number of doses with acute medication
Number of days with sick leave
Beyond the preview
Go deeper on NCT06485336.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06485336.